A novel percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla in the treatment of COPD combined with pulmonary bullae.

🎯 Background & Rationale

Giant pulmonary bullae (GEB) secondary to chronic obstructive pulmonary disease (COPD) severely compromise lung mechanics and gas exchange. Traditional surgical approaches (thoracotomy or video-assisted thoracoscopic surgery [VATS]) carry prohibitive risks of morbidity and mortality in fragile, high-risk COPD patients with poor baseline lung function. While bronchoscopic lung volume reduction (BLVR) techniques like endobronchial valves (EBVs) offer minimally invasive alternatives, they are frequently constrained by collateral ventilation or technical unsuitability in single giant bullae. This study addresses the clinical need for a less invasive, cost-effective, and repeatable therapeutic strategy by evaluating a staged percutaneous aspiration sclerotherapy technique utilizing lauromacrogol, autologous blood, and thrombin.

👥 Study Design & Population

• Study Type: Retrospective single-center observational case series.
• Population: 40 COPD patients with giant pulmonary bullae (GEB occupying $\ge 30%$ of a unilateral hemithorax or measuring $\ge 5\text{ cm}$) who were deemed unable to tolerate surgical bullectomy due to advanced age, poor cardiopulmonary reserve ($\text{FEV}_1 < 50%$ predicted), or severe comorbidities.
• Intervention: A three-stage percutaneous CT-guided interventional protocol:
  1. Injection of the sclerosing agent lauromacrogol.
  2. Aspiration of gas coupled with the injection of autologous blood.
  3. A final reinforcement stage utilizing autologous blood combined with topical thrombin powder.

📈 Methodology & Rigor

• Statistical Methods: The authors utilized SPSS 22.0 to perform homogeneity of variance and normality tests, followed by paired or two-independent-sample $t$-tests for quantitative data (expressed as mean $\pm$ standard deviation) and univariate analyses to screen risk factors associated with complications.
• Data Handling: Pre- and postoperative evaluations included high-resolution CT planimetry (evaluated by blinded researchers), pulmonary function testing (PFTs), arterial blood gas (ABG) analysis, 6-minute walk tests (6MWT), modified Medical Research Council (mMRC) dyspnea scores, and St. George’s Respiratory Questionnaire (SGRQ) scores assessed at baseline and 1 month post-procedure.
• Rigorousness: While prospective data collection for safety and functional metrics was structured, the single-center retrospective design without a concurrent control or comparator arm (such as standard surgical bullectomy or EBVs) limits broad methodological rigor.

🔬 Key Findings

• Bullae Size & Lung Function: The average baseline GEB diameter was $12.67 \pm 2.49\text{ cm}$, which significantly decreased post-treatment ($p < 0.001$, overall effective rate of $87.5%$).
• Functional & Quality of Life Outcomes: Significant improvements ($p < 0.001$) were observed in $\text{FEV}_1$ ($1.13$ to $1.33\text{ L}$), $\text{FEV}_1%$ predicted ($31.58%$ to $36.63%$), $\text{FVC}$, 6MWT distance ($243.50$ to $282.80\text{ m}$), mMRC scores, and SGRQ quality-of-life scores ($66.75$ to $57.52$).
• Gas Exchange: $\text{PaO}_2$ significantly improved ($79.41$ to $85.19\text{ mmHg}, p = 0.006$), while $\text{PaCO}_2$ decreased without statistical significance ($p > 0.05$).
• Complications: Pneumothorax occurred in $35.0%$ ($n=14$) of patients, requiring chest tube drainage in 12 cases. Mild hemoptysis occurred in 30.0% ($n=12$), fever in $20.0%$ ($n=8$), and chest pain in $22.5%$ ($n=9$). Univariate analysis identified the number of needle punctures as a significant risk factor for pneumothorax ($p = 0.002$).

⚖️ Critical Appraisal

• Internal Validity: The retrospective, single-arm nature introduces inevitable selection and performance biases. Without a control group, it is difficult to isolate the precise therapeutic contribution of the staged sclerosants versus simple aspiration/decompression.
• External Validity: Generalizability is limited; the cohort was overwhelmingly male ($97.5%$) from a single center in China, and the technique is strictly tailored to single dominant bullae rather than diffuse, homogeneous emphysema or complex multi-loculated cysts.
• Safety Profile: A $35%$ pneumothorax rate is clinically significant, underscoring that crossing the pleural space multiple times across three separate stages carries substantial risk. Optimization of the puncture trajectory to strictly avoid aerated parenchyma is paramount.

💡 The Clinical Bottom Line

Staged percutaneous aspiration sclerotherapy (using lauromacrogol, autologous blood, and thrombin) is a feasible, minimally invasive alternative to surgery that yields significant short-term improvements in lung function, exercise capacity, and quality of life for surgically unfit COPD patients with giant pulmonary bullae. However, because of the notable pneumothorax rate ($35%$) and lack of long-term follow-up beyond one month, interventional pulmonologists should reserve this technique for carefully selected, highly symptomatic candidates who have failed or are ineligible for standard endoscopic or surgical volume reduction modalities.